Just as the skin is a unique system within the human body, dermatology requires specialized knowledge and unique skills.
Galderma was founded with the goal of establishing a pharmaceutical company exclusively focused on dermatology.
For over 30 years, all our resources have been channeled in a single direction: to provide innovative medical solutions that meet the needs of dermatology patients and physicians with a particular focus on acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer aned medical solutions for skin senescence. The skin conditions we treat can have strong psychological and social implications in the everyday lives of our patients. By treating these conditions, we help people preserve, restore and maintain a healthy skin and improve their quality of life.
Today, Galderma has nearly 4000 employees in 31 affiliates around the world. In 2011, Galderma acquired Q-Med, a Swedish medical device company and leader in the aesthetic market. With approximately 20% of sales invested each year to discover and develop new products and access innovative technologies, Galderma’s R&D center in Sophia-Antipolis, France, is one of the largest sites in the world dedicated exclusively to dermatology, now complemented by a state-of-the-art R&D facility in Uppsala, Sweden. Galderma’s important investments in R&D, extensive product portfolio, global presence and sales force coverage and expertise in three key business segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) contribute to maintaining its strong leadership in dermatology.
We are committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world.